![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
USOTC:ALIOF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 278.50 | 0.00 | 01:00:00 |
Good news flowed in at Gilead Sciences, Inc. (GILD) when the U.S. Food and Drug Administration (FDA) approved its HIV single tablet regimen Complera (once daily) for an additional indication. Gilead gained FDA approval of Complera in certain virologically-suppressed (HIV RNA <50 copies/mL) adults on a stable antiretroviral regimen to replace their current antiretroviral therapy regimen.
Approval was gained on the basis of encouraging data from a phase III open-label, randomized study (SPIRIT: study 106). Complera, a fixed-dose combination of Gilead’s Truvada (which in turn is a fixed-dose drug of Gilead's Viread and Emtriva) and Johnson and Johnson’s (JNJ) Edurant, was initially launched in the U.S. in 2011 as a first-line therapy for HIV. Following the label expansion, HIV infected adults can switch to Complera therapy from other treatment regimens.
Complera is marketed as Eviplera in the EU since 2011 as a first-line therapy in HIV infected adults. Currently, the regimen is also approved in the EU for treating HIV infected adults without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor class, Gilead’s Viread or Emtriva. Moreover, the viral load is less than or equal to 100,000 HIV-1 RNA copies/mL.
Approval of Complera/ Eviplera for the new indication will further boost the drug’s sales potential. The combination drug has performed well since launch with sales in the third quarter of 2013 climbing 12% sequentially to $210.7 million.
Gilead, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biopharma space include Actelion Ltd. (ALIOF) and Vanda Pharmaceuticals Inc. (VNDA). Both stocks carry a Zacks Rank #1 (Strong Buy).
1 Year Chart |
1 Month Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions